Ernst & Young accounting firm
Maples Corporate Services Limited's office PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of Business
Room 901, 9 / F, Nan Fung Building, 88 Connaught Road Central and 173 des Voeux Road Central, Hong Kong
Hong Kong motherboard
Deqi Pharmaceutical Co., Ltd. is a clinical stage biopharmaceutical company in the Asia-Pacific region focusing on the innovation of antineoplastic drugs. The company is mainly engaged in the discovery, development, production and commercialization of biotechnology products. The company's key products include ATG-010 (selinexor) for the treatment of recurrent / refractory multiple myeloma, recurrent / refractory diffuse large B-cell B-cell lymphoma and non-small cell lung cancer, and ATG-008 (onatasertib) for a variety of indications, including hepatocellular carcinoma and non-small cell lung cancer. The company mainly operates in the Asia-Pacific region.
Deqi Pharmaceutical is a leading biopharmaceutical company focused on innovative antineoplastic drugs. Our uniqueness comes from our industry-leading R & D capabilities and differentiated strategic approaches to developing new antineoplastic therapies. Our vision is to discover, develop and commercialize the world's first, unique and / or best-of-class therapy, treat patients without borders and improve their living standards.
Through the effective use of resources, outstanding ability in target selection and differentiated R & D strategy, Deqi Pharmaceuticals has established a strong and highly coordinated R & D pipeline of 12 products, including two late clinical assets and four early clinical assets. In addition, we are developing six pre-clinical R & D drugs that focus on innovative targets or mechanisms and have the potential to be number one in their class to address huge unmet medical needs. Moreover, these drugs target the key pathways of carcinogenesis and have the potential to be combined with each other.
Since its inception, we have established a solid R & D framework in the Asia-Pacific region and have a pan-Asia-Pacific clinical R & D capability. At this stage, we are establishing a commercialization team in the Asia-Pacific region to support the recent product launch, which is made up of multinational leaders with rich business experience and experienced practitioners who have in-depth knowledge of the developments in each local market.